Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Quarterly results
Inv. presentation
Asset disposition
|
|
RAPT Therapeutics, Inc. (RAPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 10.4% stake in RAPT THERAPEUTICS INC |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2023. “In 2023, we are continuing to focus on advancing our two lead programs, RPT193 and FLX475,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “In the first quarter, we expanded our RPT193 program with the initiation of a Phase 2a clinical trial in asthma. We co..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/14/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us ...",
"29 8 15 43" |
|
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 5.3% stake in RAPT Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 9.9% stake in RAPT THERAPEUTICS INC |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
SC 13G/A
| FMR LLC reports a 11.6% stake in RAPT THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 8.7% stake in RAPT THERAPEUTICS INC |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/13/2023 |
SC 13D/A
| COLUMN GROUP II, LP reports a 13.1% stake in RAPT THERAPEUTICS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/18/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/17/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 09/06/2022 |
8-K
| Investor presentation |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|
|
|